IMI2 - Call 23

IMI2 - Call 23 was launched on 23 June 2020 with the following topics:

  • Returning clinical trial data to study participants within a GDPR compliant and approved ethical framework
  • Modelling the impact of monoclonal antibodies and vaccines on the reduction of antimicrobial resistance
    This topic is part of IMI’s Antimicrobial Resistance (AMR) Accelerator programme.
  • A platform for accelerating biomarker discovery and validation to support therapeutics development for neurodegenerative diseases
  • Optimal treatment for patients with solid tumours in Europe through artificial intelligence
  • Shortening the path to rare disease diagnosis by using new born genetic screening and digital technologies
  • Behavioural model of factors affecting patient adherence

More information on the topics can be found in IMI's press release and in the Call text. Other relevant documents can be found on the  IMI2 Call documents page.

Projects

The projects resulting from IMI2 - Call 23 are:

  • BEAMER - Behavioral and adherence model for improving quality, health outcomes and cost-effectiveness of healthcare
    factsheet | website
  • EPND - European Platform for Neurodegenerative Diseases
    factsheet | website
  • FACILITATE - Framework for clinical trial participants data reutilization for a fully transparent and ethical ecosystem
  • OPTIMA - Optimal treatment for patients with solid tumours in Europe through artificial intelligence
    factsheet | website
  • PRIMAVERA - Predicting the impact of monoclonal antibodies & vaccines on antimicrobial resistance
    factsheet 
  • SCREEN4CARE - Shortening the path to rare disease diagnosis by using newborn genetic screening and digital technologies
    factsheet | website

Call statistics

  • Proposals submitted: 56
  • Inadmissible & ineligible proposals: 2
  • Proposals recommended for funding: 6
  • Proposals not recommended for funding: 48

Reports